Tesamorelin vs Sermorelin: Structural and Pharmacologic Comparison

The short version

The tesamorelin vs sermorelin question comes down to chain length and stability. Both are analogues of GHRH (the brain's "make growth hormone" signal), and both work the same way — they tell the pituitary gland to release the body's own growth hormone. The difference is size: tesamorelin is the full 44-amino-acid version with a chemical cap that resists breakdown, while sermorelin is a shorter 29-amino-acid fragment without that cap. This page compares their structure and pharmacology only. It does not recommend either, and gives no dosing.

Structural comparison

The structural difference is the whole story. Tesamorelin is a synthetic analogue of full-length human GHRH(1-44) — all 44 amino acids — bearing a trans-3-hexenoic acid group on its N-terminus ^[8]. That fatty-acid cap is the defining modification: it blocks DPP-IV, the enzyme that cleaves and inactivates native GHRH within minutes, so tesamorelin survives long enough in plasma to act ^[8].

Sermorelin, by contrast, is GHRH(1-29) — the first 29 amino acids of GHRH, the minimal sequence that retains full biological activity at the receptor. It carries no DPP-IV-blocking N-terminal modification. So while both molecules engage the same GHRH receptor, tesamorelin is the longer, deliberately stabilized analogue and sermorelin is the shorter, unmodified fragment. They are distinct molecules, not interchangeable names.

This structural distinction is sharp enough that anti-doping analytical methods are designed to tell tesamorelin apart from sermorelin and other GHRH-type peptides — they are chemically separable, not variants of one substance.

Pharmacologic comparison

Both compounds are GHRH-receptor agonists: each binds the GHRH receptor on pituitary somatotrophs and stimulates pulsatile growth-hormone release through the Gs/cAMP/PKA cascade, raising IGF-1 downstream ^[4]. The mechanistic family is identical. Where they diverge in the published record is depth of human evidence. Tesamorelin carries an unusually extensive clinical dataset for this compound class — two pivotal Phase 3 RCTs in HIV-associated lipodystrophy (n=412 and the 52-week program) ^[1][2], a JAMA hepatic-fat trial ^[3], population pharmacokinetic and PK-PD analyses ^[6][7], a drug-interaction study ^[10], and a 2026 five-RCT meta-analysis ^[13]. The visceral-fat and IGF-1 figures on this site come from that tesamorelin record specifically.

The pharmacokinetic consequence of the structural difference is the more durable plasma activity tesamorelin gains from DPP-IV resistance. Native GHRH — and, by extension, an unmodified GHRH(1-29) fragment — is exposed to rapid DPP-IV cleavage; tesamorelin's N-terminal cap blocks that pathway, slowing degradation in rat, dog, and human plasma ^[8]. Even so, tesamorelin's parent peptide is itself short-lived, clearing in the tens-of-minutes range, with the sustained effect arising from the downstream IGF-1 response rather than prolonged drug exposure ^[6].

This page makes no efficacy claim about sermorelin and recommends neither compound. It is a structural and pharmacologic comparison of two GHRH analogues, drawn from the tesamorelin literature.

Why the distinction matters for the literature

Because tesamorelin and sermorelin are different molecules, evidence for one does not transfer to the other. Tesamorelin's DPP-IV-resistant full-length structure ^[8] and its dedicated trial program ^[1][2][3] are what underpin the visceral-fat, IGF-1, and liver-fat findings catalogued in the visceral-fat research on this site. Sermorelin's GHRH(1-29) profile is its own literature. Conflating the two — treating a tesamorelin trial result as if it described sermorelin, or vice versa — is a category error this comparison is meant to prevent. Both are GHRH-receptor agonists; only tesamorelin carries the body of evidence summarized here ^[15].

The practical upshot for a reader: a figure like the 15.2% visceral-fat reduction ^[1] or the 81.0% IGF-1 rise ^[1] is a tesamorelin figure, measured with tesamorelin, in a tesamorelin trial. It is not a generic "GHRH analogue" number and should not be quoted as one for sermorelin or any other peptide in the class. When this site files a result to its source, the molecule that was actually administered is part of the citation. That discipline is the entire reason for separating the two on a structural and pharmacologic basis rather than collapsing them into one "GHRH peptide" story.